Moderna, Inc. Stock

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:23:09 2024-05-29 EDT 5-day change 1st Jan Change
145.3 USD -5.17% Intraday chart for Moderna, Inc. -12.01% +44.50%
Sales 2024 * 4.18B 5.71B Sales 2025 * 4.84B 6.61B Capitalization 58.71B 80.17B
Net income 2024 * -2.7B -3.69B Net income 2025 * -1.97B -2.69B EV / Sales 2024 * 12.6 x
Net cash position 2024 * 6.25B 8.53B Net cash position 2025 * 3.94B 5.38B EV / Sales 2025 * 11.3 x
P/E ratio 2024 *
-21.7 x
P/E ratio 2025 *
-29.8 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.05%
1 week+6.62%
Current month+38.88%
1 month+41.89%
3 months+57.16%
6 months+95.96%
Current year+54.05%
More quotes
1 week
148.50
Extreme 148.5001
170.47
1 month
109.00
Extreme 109
170.47
Current year
84.06
Extreme 84.06
170.47
1 year
62.55
Extreme 62.55
170.47
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
Director of Finance/CFO 47 22-09-05
President 48 12-12-31
Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 74 20-06-30
Director/Board Member 67 19-12-10
More insiders
Date Price Change Volume
24-05-29 143.7 -6.22% 2 785 201
24-05-28 153.2 -8.05% 6,636,483
24-05-24 166.6 +1.59% 5,052,591
24-05-23 164 +0.42% 7,120,701
24-05-22 163.3 +13.67% 13,592,711

Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
153.2 USD
Average target price
138.5 USD
Spread / Average Target
-9.59%
Consensus